Want to see LH full AI Analyst Report?
LH Stock Chart & Stats
$296.77
$4.40(1.48%)
At close: 4:00 PM EDT
$296.77
$4.40(1.48%)
Day’s Range― - ―
52-Week Range$244.52 - $316.11
Previous Close$301.91
Volume649.63K
Average Volume (3M)669.45K
Market Cap
$25.35B
Enterprise Value$29.60K
Total Cash (Recent Filing)$141.80M
Total Debt (Recent Filing)$6.77B
Price to Earnings (P/E)25.4
Beta0.28
Next Earnings
Oct 22, 2026EPS Estimate
4.65Next Dividend Ex-DateN/A
Dividend Yield0.93%
Share Statistics
EPS (TTM)12.17
Shares Outstanding82,000,000
10 Day Avg. Volume791,792
30 Day Avg. Volume669,453
Financial Highlights & Ratios
PEG Ratio1.28
Price to Book (P/B)2.42
Price to Sales (P/S)1.50
P/FCF Ratio17.31
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$335.22Price Target Upside12.96% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)18.24
Revenue Forecast (FY)$14.74B
Bulls Say, Bears Say
Bulls Say
Diversified, Scale-driven Business ModelLabcorp's two-segment model (Diagnostics and Drug Development) and global scale provide durable revenue diversification. Clinical testing and CRO services expose the company to multiple secular demand drivers, smoothing cycles and enabling cross-selling and operational leverage over the next several quarters.
Improving Revenue And Margins With Raised GuidanceRecent top-line growth and 70bp operating margin expansion signal improving operating leverage. Management's upward guidance and higher EPS midpoint reflect sustainable operational momentum and stronger profitability assumptions for the coming 2–6 months, supporting durable earnings improvement.
Robust BLS Backlog And Book-to-billAn $8.7B BLS backlog and >1 book-to-bill provide visible near-term revenue for the Drug Development segment. This backlog-driven revenue conversion supports predictable, higher-margin central lab workloads and underpins multi-quarter growth visibility for the CRO business.
Bears Say
High Absolute Leverage Despite Manageable RatiosWhile leverage ratios are within industry norms, the large absolute debt stock limits financial flexibility for opportunistic investments or cushioning during downturns. Elevated interest and principal obligations increase vulnerability to cash-flow timing issues over the medium term.
Free Cash Flow Decline And Sub‑optimal ConversionA meaningful decline in FCF and less-than-1x earnings-to-cash conversion reduce internal funding for capex, M&A, and buybacks. Persistent cash conversion variability heightens reliance on external financing and constrains capital allocation flexibility over the coming quarters.
Regulatory And Payer Reimbursement UncertaintyLegislative and regulatory changes to reimbursement (PAMA/RESULTS Act) and payer dynamics can structurally compress realized prices for diagnostics. This persistent policy risk could reduce revenue per test and margin sustainability absent offsetting price/mix gains.
LH FAQ
What was Labcorp Holdings’s price range in the past 12 months?
Labcorp Holdings lowest stock price was $244.52 and its highest was $316.11 in the past 12 months.
What is Labcorp Holdings’s market cap?
Labcorp Holdings’s market cap is $25.35B.
When is Labcorp Holdings’s upcoming earnings report date?
Labcorp Holdings’s upcoming earnings report date is Oct 22, 2026 which is in 81 days.
How were Labcorp Holdings’s earnings last quarter?
Labcorp Holdings released its earnings results on Jul 30, 2026. The company reported $4.99 earnings per share for the quarter, beating the consensus estimate of $4.779 by $0.211.
Is Labcorp Holdings overvalued?
According to Wall Street analysts Labcorp Holdings’s price is currently Undervalued.
Does Labcorp Holdings pay dividends?
Labcorp Holdings pays a Quarterly dividend of $0.72 which represents an annual dividend yield of 0.93%. See more information on Labcorp Holdings dividends here
What is Labcorp Holdings’s EPS estimate?
Labcorp Holdings’s EPS estimate is 4.65.
How many shares outstanding does Labcorp Holdings have?
Labcorp Holdings has 82,000,000 shares outstanding.
What happened to Labcorp Holdings’s price movement after its last earnings report?
Labcorp Holdings reported an EPS of $4.99 in its last earnings report, beating expectations of $4.779. Following the earnings report the stock price went up 2.728%.
Which hedge fund is a major shareholder of Labcorp Holdings?
Currently, no hedge funds are holding shares in LH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Labcorp Holdings Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$335.22 (12.96% Upside)
$335.22 (12.96% Upside)
Blogger Sentiment
Bullish
LH Sentiment 75%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 60.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 4.2%
Last 30 Days ▼ 4.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
12.03%
12-Months-Change
Fundamentals
Return on Equity
0.93%
Trailing 12-Months
Asset Growth
2.62%
Trailing 12-Months
Company Description
Labcorp Holdings
Labcorp Holdings, Inc. offers vital diagnostic laboratory services, enabling medical professionals, healthcare facilities, pharmaceutical firms, scientific investigators, and patients to make well-informed and confident choices. The company commenced operations on April 16, 2024, and its main office is situated in Burlington, NC.
LH Company Deck
LH Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a strong operational and financial quarter: revenue growth, margin expansion, double-digit adjusted EPS growth, raised guidance, robust BLS backlog and book-to-bill, and multiple product/partnership launches. Headwinds highlighted were a meaningful quarter-over-quarter drop in free cash flow (timing and capex), a modest ACA-related volume headwind (~30 bps), prior and improving Early Development softness, higher patient-pay mix, and elevated absolute debt with relatively low cash on hand. On balance the positives around revenue, margins, guidance increases, product/market progress, and capital returns materially outweigh the cited challenges.View all LH earnings summariesLH Revenue Breakdown
77.96% Dx
22.21% BLS
-0.16% Intercompany eliminations

LH Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
$335.22
▲(12.96% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
Ownership Overview
0.32% Insiders
32.43% Mutual Funds
5.55% Other Institutional Investors
34.90% Public Companies and
Individual Investors









